<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00747500</url>
  </required_header>
  <id_info>
    <org_study_id>Y-97-52030-213</org_study_id>
    <nct_id>NCT00747500</nct_id>
  </id_info>
  <brief_title>Non Interventional Post Marketing Programme in Acromegaly</brief_title>
  <official_title>An Observational, Multicentre, Open Label, Non Interventional Programme to Assess the Long-term Safety and Efficacy of Somatuline® Autogel® in the Treatment of Acromegaly When Administered by Patients or Their Partners (&quot;Home Injection Group&quot;) or Administered by Healthcare Professionals.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study, is to assess the safety and local tolerability of the long-term
      use of Somatuline Autogel when administered by patients or their partners (&quot;Home Injection
      Group&quot;) and the safety and local tolerability in patients receiving their injection from a
      healthcare professional (HCP) (&quot;Reference Group&quot;).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>safety and local tolerability of Somatuline Autogel when administered by patients or their partners or from a healthcare professional</measure>
    <time_frame>End of observational period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>efficacy of Somatuline Autogel in both groups</measure>
    <time_frame>End of observational period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>training requirements for patients / partners to perform home injection of Somatuline Autogel</measure>
    <time_frame>End of observational period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acceptability of home injections to patients, partners and healthcare professionals</measure>
    <time_frame>End of observational period</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">42</enrollment>
  <condition>Acromegaly</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Acromegaly seen in routine clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must give written (personally signed and dated) informed consent for their
             data to be included in the database for this post-marketing surveillance programme and
             any subsequent analysis.

          -  The patient must have been receiving treatment with Somatuline Autogel at a stable
             dose for at least 4 months.

          -  The patient must have a diagnosis of acromegaly.

          -  The patient must be at least 18 years of age.

          -  For patients receiving or intending to receive Somatuline Autogel by home injection:

               -  The patient must be able to store Somatuline Autogel safely in a refrigerator in
                  their own home and either collect it from their general practitioner/pharmacy on
                  a monthly basis, or receive the medication by a home delivery service.

        Exclusion Criteria:

          -  The patient is pregnant or breast-feeding, unless continued treatment with Somatuline
             Autogel is clearly needed (as determined by the treating clinician).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Fairey, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnsley General Hospital</name>
      <address>
        <city>Barnsley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Coventry &amp; Warwickshire</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2008</study_first_submitted>
  <study_first_submitted_qc>September 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2008</study_first_posted>
  <last_update_submitted>April 22, 2013</last_update_submitted>
  <last_update_submitted_qc>April 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

